Leukotrienes as mediators of asthma

Pulmonary Pharmacology and Therapeutics

Volumn 14, Issue 1, 2001, Pages 3-19

  Nicosia, S ^a   Capra, V ^a   Rovati, G E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

BLT; CysLT1; CysLT2; Cysteinyl LT; LTB4

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; CINALUKAST; IRALUKAST; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; POBILUKAST; PRANLUKAST; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; BREATHING MUSCLE; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCUS; DRUG MECHANISM; HEADACHE; HUMAN; INFLAMMATION; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; RAT; REVIEW; SMOOTH MUSCLE TONE;

EID: 0035131860     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.2000.0262     Document Type: Review

References (210)

1. Leukotriene C: Slow-reacting substance from murine mastocytoma cells
2. Leukotrienes: A new class of mediators of immediate hypersensitivity reactions and inflammation
3. The biologically active leukotrienes
4. 4 and asthma
5. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks
6. Leukotrienes and airway responses
7. Regulation by leukotrienes
8. 4
9. 4
10. Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells
11. Diversity of group types, regulation, and function of phospholipase A2
12. Molecular cloning and amino acid sequence of human 5-lipoxygenase
13. Cloning of the cDNA for human 5-lipoxygenase
14. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages
15. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
16. 4
17. 4 synthase. Organization, nucleotide sequence, and chromosomal localization to 5q35
18. 4 synthase promoter polymorphism and risk of aspirin-induced asthma
19. 4-synthesis deficiency: A new inborn error of metabolism linked to a fatal developmental syndrome
20. ATP-dependent leukotriene export from mastocytoma cells
21. 4 by human eosinophils
22. 4 20-hydroxylase from polymorphonuclear leukocytes
23. Metabolic inactivation of leukotrienes
24. Metabolism of eicosanoids in mammalian cells
25. 4 elimination and metabolism in normal human subjects
26. Prostanoid and leukotriene receptors: A progress report from the IUPHAR working parties on classification and nomenclature
27. 4 that mediates chemotaxis
28. 4
29. 4 binding to human neutrophils
30. 4 binding sites in guinea-pig alveolar macrophages
31. 4 receptors on guinea pig alveolar eosinophils
32. Differential uncoupling of chemoattractant receptors from G proteins in retinoic acid-differentiated HL-60 granulocytes
33. 4 receptor in human myeloid cells
34. 4 receptor from sheep lung membranes
35. 4 receptor expressed on eosinophils
36. 4 receptor
37. 4 receptor: Comparison to its human orthologue
38. 4 receptor
39. 4 pathway to inflammation control
40. 4 receptor antagonist CP-105696
41. 4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs
42. 4 aerosol in rhesus monkeys
43. 4 receptor antagonist, LY293111, on allergen induced responses in asthma
44. 4 receptor, BLT2: A new therapeutic target in inflammation and immunological disorders
45. 4 receptor
46. 4 receptor
47. 1 receptor
48. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor
49. 4 receptor in guinea pig lung
50. 2) receptor
51. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor
52. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents
53. The leukotrienes: Mediators of chronic inflammation in asthma
54. 4
55. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist
56. 4 receptor antagonist
57. 4 receptor antagonist
58. 4 and antigen in vitro
59. 4
60. 4-receptor antagonist cinalukast
61. 4) induces mucus secretion from goblet cells in the guinea pig respiratory epithelium
62. 4 antagonist in the guinea pig trachea
63. A second cysteinyl leukotriene receptor in human lung
64. Leukotriene receptors and their selective antagonists
65. More on the classification of cysteinyl leukotriene receptors
66. Identification and characterization of two Cysleukotriene high-affinity binding sites with receptor characteristics in human lung parenchyma
67. Definition of pharmacological receptors
68. 4 in the guinea-pig lung
69. 4 receptor in guinea pig lung
70. 4 binding sites in guinea-pig uterus and lung preparations
71. Heterogeneity of leukotriene receptors in guinea-pig trachea
72. 4 receptor in guinea-pig trachea
73. 4 binding to rat lung membranes
74. Characterisation of leukotriene receptors on the rat lung strip
75. 4 receptors in adult and fetal human lung
76. An examination of the influence of the epithelium on contractile responses to peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobar airways
77. Pharmacologic profile of SK&F 104353: A novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways
78. In vitro pharmacology of ICI 198,615: A novel, potent and selective peptide leukotriene antagonist
79. 4 to membranes from guinea pig lung: Regulation by ions and guanine nucleotides
80. 4 receptors: Effects of cations and guanine nucleotides
81. 4 receptor solubilized in an active form. Association and dissociation with an islet-activating protein-sensitive guanine nucleotide-binding protein
82. 3H-ICI 198,615 in human lung parenchyma
83. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor
84. 4 induced calcium changes in U937 cells may utilize mechanisms additional to inositol phosphate production that are pertussis toxin insensitive but are blocked by phorbol myristate acetate
85. 4 receptor
86. 4 receptors
87. 4-induced contraction and cytosolic calcium elevation: A quantitative and simultaneous evaluation in smooth muscle
88. 2+
89. 4-induced calcium influx in human epithelial cells involves protein tyrosine phosphorylation
90. 4 receptor antagonist, SR2640, and possible relation to modulation of chemotaxis
91. 4 of increases in the cytosolic concentration of calcium in dimethylsulfoxide-differentiated HL-60 cells
92. 4-induced cyclic nucleotide changes and contractile response in guinea pig trachea
93. 4 in guinea-pig isolated lung parenchyma under equilibrium conditions
94. 4 treatment
95. 4 in human fetal lung
96. Molecular heterogeneity of leukotriene receptors: Correlation of smooth muscle contraction and radioligand binding in guinea-pig lung
97. 4 in membranes from human lung
98. 4 binding site in cellular membranes
99. 4-binding protein in rat liver cytosol as glutathione S-transferase
100. 4 binding site not coupled to contraction in human lung parenchyma
101. Pharmacology of peptide leukotrienes on ferret isolated airway smooth muscle
102. 2 on the ferret spleen strip
103. Leukotriene receptors in sheep respiratory tissue
104. BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes
105. Leukotrienes are potent constrictors of human bronchi
106. Contractile activities of several cysteine-containing leukotrienes in the guinea-pig lung strip
107. 4 of four of their novel omega- and beta-oxidative metabolities in airways of guinea-pig and man in vitro
108. 4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells
109. 4
110. 4
111. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro
112. 4 receptors
113. Characterisation of the leukotriene receptor(s) on human isolated lung strips
114. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro
115. 2 formation in isolated sensitized guinea pig lungs
116. 4 on human lung parenchyma in vitro
117. Furosemide attenuates bronchial responsiveness to antigen challenge 'in vitro'
118. 4, and histamine in normal human subjects
119. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects
120. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist
121. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
122. 4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors
123. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects
124. 4, methacholine, and histamine
125. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma
126. 4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis
127. 4 in allergen-induced increases in airway smooth muscle in the rat
128. 4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: Differential sensitivity to cysteinyl leukotriene receptor antagonists
129. Cysteinyl leukotriene receptors in the human lung: What's new?
130. 4: Effect on human and guinea-pig cardiac preparations in vitro
131. Leukotriene receptor on human pulmonary vascular endothelium
132. 4
133. 4
134. 4) in human skin
135. Regional and time-dependent effects of inflammatory mediators on airway microvascular permeability in the guinea pig
136. Role of leukotrienes in asthma
137. 2α-induced airflow obstruction and airway plasma exudation in guinea-pig: Role of thromboxane and its receptor
138. 4. Endothelial contraction
139. Aspects of eicosanoids in inflammation
140. Microvascular mechanisms in inflammation
141. 4, increase the release of mucus from human airways in vitro
142. 4 on glycoprotein and lysozyme secretion by human bronchial mucosa
143. 4 on mucin release into the cat trachea in vivo and in vitro
144. 4 enhances mucus production from submucosal glands in canine trachea in vivo
145. 4 on mucociliary and respiratory function in allergic and nonallergic sheep
146. SRS-A leukotrienes decrease the activity of human respiratory cilia
147. Immunologically induced neuromodulation of guinea pig nodose ganglion neurons
148. 4
149. 4-induced airway responses
150. Role of peptidoleukotrienes in capsaicin-sensitive sensory fibre-mediated responses in guinea-pig airways
151. 4 and histamine on bronchomotor tone
152. 4 in inflammation
153. 4 - A stereospecific stimulator for release of lysosomal enzymes from neutrophils
154. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response
155. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils
156. The inhibitory effect of TMK688, a novel anti-allergic drug having both 5-lipoxygenase inhibitory activity and anti-histamine activity, against bronchoconstriction, leukotriene production and inflammatory cell infiltration in sensitized guinea pigs
157. The importance of leukotrienes in airway inflammation in a mouse model of asthma
158. 4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody
159. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig
160. 4 receptor antagonism reduces airway hyperresponsiveness in monkeys
161. 4 in response to soluble agonists
162. 4 and granulocytic infiltration into asthmatic airways
163. 4 and methacholine on sputum cell differentials in asthma
164. Effect of Zafirlukast ('Accolate') on airway inflammation after segmental allergen challenge in patients with asthma
165. Montelukast
166. 4 in asthmatic subjects: A review
167. 4, and histamine in asthmatics
168. 4 levels during early and late asthmatic responses
169. 4 in humans. Effect of indomethacin
170. 4 after antigen challenge and in acute asthma and allergic rhinitis
171. 4 from the urine of patients with airway obstruction
172. 4 in the assessment of nocturnal asthma
173. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects
174. 4 during aspirin-induced asthma
175. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma
176. Release of leukotrienes in patients with bronchial asthma
177. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases
178. 4 during wheezing attack in asthmatic patients
179. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin
180. Inhibition of exercise-induced bronchospasm by zileuton: A 5-lipoxygenase inhibitor
181. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air
182. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin
183. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings
184. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial
185. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005
186. Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions
187. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses
188. Leukotrienes as a target in asthma therapy
189. Treatment of asthma with drugs modifying the leukotriene pathway
190. Effect of cysteinyl-leukotriene receptor antagonist ICI 204, 219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
191. 1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients
192. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353)
193. 4 receptor antagonist
194. 4-receptor antagonist
195. 4 receptor antagonist ICI 204,219 against exercise-induced asthma
196. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval
197. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
198. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction
199. Effect of zafirlukast (20 and 40 mg) on cold air induced bronchoconstriction in patients with bronchial asthma
200. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma
201. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
202. Third-generation peptidoleukotriene receptor antagonists
203. Montelukast (MK-0476), allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability
204. Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study
205. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma
206. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: Bronchoalveolar lavage fluid findings after segmental antigen challenge
207. The early onset of action of Zafirlukast ('Accolate') in patients with asthma
208. 4 receptor antagonist, in subjects with bronchial asthma
209. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter, randomized, double-blind trial
210. 4) receptor antagonist, in patients with chronic asthma